Articles from March 2023
Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session
Wednesday, March 29, 2023
Perspective, Therapeutics, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents based in-part on IP licensed from UIRF, and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, announced the presentation of extremely encouraging results regarding 212Pb-VMT-α-NET, its lead preclinical candidate for neuroendocrine tumors (NET), currently being used therapeutically in India on a compassionate use basis.
Cardio Diagnostics Holdings Inc Announces Expansion of IP Portfolio with Notice of Allowance of Patent Application
Thursday, March 9, 2023
Cardio Diagnostics Holdings, Inc., a pioneering precision cardiovascular medicine company founded by UI faculty Dr. Robert Philibert and UI graduate Dr. Meesha Dogan, today announced that China’s Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation (“UIRF”) for Chinese Patent Application No. 201780049286.4.